Skip to main content
. 2013 Nov 16;11:291. doi: 10.1186/1479-5876-11-291

Table 2.

Patient characteristics and clinical responses

No. Age Sex Target lesion Dose of peptide (mg) Number of injection Clinical response* Objective Response Response lesion Injection site reaction(Grade) CTL response
 PFS(day)
 OS (day)
 Pre-vaccination
 Post-vaccination
Pre-vaccination Post-vaccination**     WBC(/mm 3 ) Lymphocyte (%) Lymphocyte (/mm 3 ) WBC(/mm 3 ) Lymphocyte (%) Lymphocyte (/mm 3 )
1
 75
 M
 Local LNs
 1
 4
 PD
  
  
 0
 N.A.
 +
 36
 36
 7300
 7
 511
 5300
 10.5
 557
2
 57
 F
 Local
 1
 11
 PD
  
  
 1
 ++
 ++
 26
 108
 7400
 13
 962
 7900
 8
 632
3
 72
 M
 Liver
 1
 3
 -
  
  
 0
 N.T.
 N.T.
 31
 31
 7800
 11
 858
 16200
 10.5
 1701
4
 60
 M
 Lung, local LNs
 1
 19
 SD
 Yes
 Lung metastasis
 2
 +
 -
 223
 283
 5100
 21
 1071
 5200
 10.5
 546
5
 72
 F
 Primary , liver
 1
 12
 PD
  
  
 1
 +
 +++
 24
 128
 2400
 25.5
 612
 4200
 10.8
 454
6
 65
 F
 Liver
 1
 4
 PD
  
  
 0
 +
 +
 26
 40
 4500
 16.5
 743
 8000
 4.1
 328
7
 61
 F
 Local , liver
 3
 14
 SD
  
  
 2
 +
 +++
 55
 155
 4000
 25
 1000
 6400
 18.3
 1171
8
 57
 F
 Primary, liver
 3
 10
 SD
  
  
 2
 ++
 +++
 56
 145
 4500
 33
 1485
 14100
 16
 2256
9
 33
 F
 Paraaortic LNs
 3
 29
 SD
 Yes(CR)
 Liver metastasis
 3
 N.A.
 +++
 >1219
 >1219
 2500
 44.5
 1113
 3600
 33
 1188
10
 76
 M
 Liver
 3
 12
 PD
  
  
 2
 -
 ++
 27
 142
 2300
 29.5
 679
 5800
 11.5
 667
11
 55
 F
 Primary, lung
 3
 17
 SD
  
  
 1
 +
 -
 112
 225
 2600
 9
 234
 2200
 11.5
 253
12
 58
 M
 Primary
 3
 5
 PD
  
  
 0
 -
 -
 32
 32
 4500
 30
 1350
 2400
 10.7
 257
13
 58
 F
 Live, lung, LNs
 3
 10
 SD
  
  
 1
 -
 ++
 57
 97
 7100
 15.5
 1101
 9100
 10.5
 956
14
 60
 M
 Liver, LNs
 3
 17
 SD
 Yes
 Liver metastasis, LNs
 2
 +++
 +++
 169
 220
 2300
 27
 621
 4100
 19.5
 800
15
 80
 F
 Liver, LNs, lung
 3
 5
 PD
  
  
 0
 -
 +
 24
 44
 8500
 9.5
 808
 13300
 4.8
 638
16
 58
 M
 Primary, liver, lung
 3
 13
 PD
  
  
 1
 -
 ++
 28
 182
 4800
 27
 1296
 6400
 19.3
 1235
17
 49
 M
 Parimary
 3
 17
 SD
  
  
 2
 +
 +++
 169
 309
 6200
 26.5
 1643
 7900
 17.5
 1383
18
 62
 M
 Primary, liver, LNs
 3
 7
 SD
  
  
 1
 -
 +++
 93
 93
 4200
 28
 1176
 6600
 18.6
 1228
19
 61
 M
 Primarym, liver, lung, LNs
 3
 11
 SD
  
  
 2
 -
 +
 57
 105
 10200
 20.5
 2091
 28700
 9
 2583
20
 58
 M
 LNs, lung
 3
 25
 SD
  
  
 2
 +
 +++
 169
 332
 10100
 34
 3434
 7600
 19.5
 1482
21
 47
 M
 Primary, liver
 3
 13
 SD
  
  
 1
 -
 +
 56
 249
 6000
 27.5
 1650
 9600
 8
 768
22
 71
 F
 Liver, local LNs
 3
 7
 SD
 Yes
 Liver metastasis
 2
 N.A.
 ++
 89
 89
 7000
 11.5
 805
 5200
 20
 1040
23
 50
 M
 Local, LNs
 3
 6
 SD
  
  
 0
 N.A.
 -
 148
 148
 7900
 20
 1580
 11200
 19
 2128
24
 74
 M
 Bone
 3
 21
 SD
 Yes
 Bone metastasis
 2
 N.A.
 +++
 415
 495
 3800
 16
 608
 5600
 17.8
 997
25
 69
 F
 Primary
 3
 2
 -
  
  
 0
 N.T.
 N.T.
 11
 11
 7600
 21.5
 1634
 7400
 20.5
 1517
26
 80
 M
 Liver, lung
 3
 18
 SD
  
  
 1
 +
 +++
 112
 207
 6600
 24
 1584
 7500
 21.5
 1613
27
 44
 M
 Liver, lung, local LNs
 3
 24
 SD
 Yes
 Lung and liver metastasis
 1
 +
 -
 115
 317
 2900
 23.5
 682
 4000
 25.5
 1020
28
 61
 F
 Peritoneal, local LNs
 3
 9
 SD
 Yes
 Peritoneal metastasis
 0
 -
 -
 69
 69
 9000
 26.5
 2385
 11200
 7.5
 840
29
 46
 M
 Liver
 3
 10
 SD
  
  
 2
 -
 +++
 52
 388
 4000
 26
 1040
 5600
 24.6
 1378
30
 64
 F
 Liver
 3
 9
 SD
  
  
 2
 -
 +++
 56
 69
 4800
 26.5
 1272
 8900
 7.1
 632
31 68 F Liver 3 9 SD Yes Liver metastasis 2 + +++ 56 82 6800 33 2244 8300 19.5 1619

*Clinical response was evaluated one month after vaccination. PD, Progressive disease; SD, Stable disease; CR, Complete response; OR, Objective response.

**Best CTL response after vaccination. CTL responses were evaluated and classified based on the algorithm as described in Methods.

N.T. (Not Tested); CTL response was not tested in the samples in which PD was observed within one course of the treatment.

N.A. (Not Analyzed); CTL response was not analyzed because of the poor viability during the in vitro stimulation.